Iclusig is an oral drug developed by ARIAD Pharmaceuticalsfor the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia(ALL).

The global Iclusig market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Iclusig volume and value at global level, regional level and company level. From a global perspective, this report represents overall Iclusig market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Iclusig in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Iclusig manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
ARIAD Pharmaceuticals
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
45mg
15mg

Segment by Application
CML
ALL